Molecular testing in lung cancer: Where to draw the line?
from Archives of Pathology & Laboratory Medicine
The last decade has seen a complete transformation of the diagnostic and treatment landscape in the management of non–small cell lung cancer. Following the initial discovery of recurrent epidermal growth factor receptor mutations and then anaplastic lymphoma kinase translocations marking key subsets of NSCLCs highly responsive to targeted therapy, up-front reflex molecular testing has become requisite, impacting the workflow of pathology departments around the world in major ways and calling for careful tissue stewardship and close attention to proper triaging/processing/turnaround times.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063